Stock Events

Stock Events

Infant Bacterial Therapeutics AB 

€4.34
0
-€0.18-4.09% Tuesday 06:01

Statistics

Day High
4.34
Day Low
4.34
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
56.43M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q3 2025
Q4 2025
Next
-0.13
-0.11
-0.09
-0.07
Expected EPS
-0.1271065509
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-16.21MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 9IB.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Evelo Biosciences
EVLO
Mkt Cap9,491
Evelo Biosciences, Inc. focuses on developing therapies for inflammatory diseases, which overlaps with IFTBF's focus on preventing necrotizing enterocolitis in infants.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics, Inc. develops biopharmaceuticals targeting various diseases, including those affecting children, similar to IFTBF's pediatric focus.
Ultragenyx Pharmaceutical
RARE
Mkt Cap3.33B
Ultragenyx Pharmaceutical Inc. works on therapies for rare genetic diseases in children, aligning with IFTBF's niche in specialized pediatric care.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical Inc. develops enzyme replacement therapies for rare disorders, including pediatric patients, competing in the same rare disease space as IFTBF.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals Incorporated focuses on treating cystic fibrosis, a serious disease in children, competing for similar pediatric healthcare resources.
Abeona Therapeutics
ABEO
Mkt Cap246.65M
Abeona Therapeutics Inc. targets rare genetic pediatric diseases, directly competing in IFTBF's market of specialized treatments for children.
uniQure N.V.
QURE
Mkt Cap4.17B
uniQure N.V. specializes in gene therapy, including treatments for children, which competes with IFTBF's focus on innovative therapies for infants.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics AG works on gene-editing therapies, including potential treatments for diseases in children, overlapping with IFTBF's focus on pediatric healthcare.

About

Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is based in Stockholm, Sweden.
Show more...
CEO
ISIN
SE0008015259
WKN
000A2AFQL

Listings

F
DE
9IB.F
ST
SE
IBT-B.ST
Grey Market
US
IFTBF

0 Comments

Share your thoughts

FAQ

What is Infant Bacterial Therapeutics AB stock price today?▼
The current price of 9IB.F is €4.34 EUR — it has decreased by -4.09% in the past 24 hours. Watch Infant Bacterial Therapeutics AB stock price performance more closely on the chart.
What is Infant Bacterial Therapeutics AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Infant Bacterial Therapeutics AB stocks are traded under the ticker 9IB.F.
What is Infant Bacterial Therapeutics AB market cap?▼
Today Infant Bacterial Therapeutics AB has the market capitalization of 56.43M
When is the next Infant Bacterial Therapeutics AB earnings date?▼
Infant Bacterial Therapeutics AB is going to release the next earnings report on May 06, 2026.
What were Infant Bacterial Therapeutics AB earnings last quarter?▼
9IB.F earnings for the last quarter are -0.13 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Infant Bacterial Therapeutics AB revenue for the last year?▼
Infant Bacterial Therapeutics AB revenue for the last year amounts to 0 EUR.
What is Infant Bacterial Therapeutics AB net income for the last year?▼
9IB.F net income for the last year is -16.21M EUR.
When did Infant Bacterial Therapeutics AB complete a stock split?▼
Infant Bacterial Therapeutics AB has not had any recent stock splits.